"This is an important milestone for the ADAPT trial as we continue to be pleased with the pace of enrollment and the opportunity to advance this promising, fully personalized immunotherapy in newly diagnosed, synchronous metastatic RCC patients," said
AGS-003 is an investigational, fully personalized immunotherapy for cancer comprised of autologous tumor RNA-loaded dendritic cells. The ADAPT trial is a randomized, international Phase III trial comparing standard targeted therapy plus AGS-003 to standard therapy alone in 450 mRCC patients. In total, more than 225 patients at more than 120 active ADAPT trial sites have been enrolled and randomized in the trial. In addition, more than 600 patients have participated in the initial tumor collection phase of the trial.
In the Company's completed Phase II study, treatment with AGS-003 in combination with sunitinib in unfavorable risk mRCC patients resulted in median progression free survival of 11.2 months and median overall survival of 30.2 months. In recently published findings from the International mRCC
Adverse events associated with the use of AGS-003 in the Phase II study were minor with no grade 3 or 4 adverse events and no evidence of autoimmunity.
About the Arcelis™ Technology Platform
Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen - loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.
Forward Looking Statements
Any statements in this press release about the Company's future expectations, plans and prospects, including statements about the Company and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether the Company's cash resources will be sufficient to fund our continuing operations for the period anticipated; whether the Company will obtain the financing needed to complete the leasing, build-out and equipping of a new commercial manufacturing facility when needed; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials;
whether findings regarding treatment with sunitinib from clinical trials conducted by third parties or in independent databases will be predictive of the outcome of our phase 3 clinical trial; whether AGS-003 will advance through the clinical trial process on a timely basis and receive approval from the
CONTACT: Media contact:
Adam DaleyBerry & Company Public Relations [email protected] 212-253-8881 Investor contact: Angeli Kolhatkar Burns McClellan[email protected] 212-213-0006
News Provided by Acquire Media